OSE Immunotherapeutics (XPAR:OSE) Accounts Payable & Accrued Expense : €6.51 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics Accounts Payable & Accrued Expense?

OSE Immunotherapeutics's quarterly accounts payable & accrued expense increased from Dec. 2022 (€5.03 Mil) to Jun. 2023 (€12.10 Mil) but then declined from Jun. 2023 (€12.10 Mil) to Dec. 2023 (€6.51 Mil).

OSE Immunotherapeutics's annual accounts payable & accrued expense increased from Dec. 2021 (€3.13 Mil) to Dec. 2022 (€5.03 Mil) and increased from Dec. 2022 (€5.03 Mil) to Dec. 2023 (€6.51 Mil).

OSE Immunotherapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for OSE Immunotherapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics Accounts Payable & Accrued Expense Chart

OSE Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

4.40

7.55

3.13

5.03

6.51

OSE Immunotherapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.13	15.79	5.03	12.10	6.51

OSE Immunotherapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

OSE Immunotherapeutics (XPAR:OSE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

6OP:Germany

Address

22, Boulevard Benoni Goullin, Nantes, FRA, 44200

Website

http://www.ose-immuno.com

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines